Menu
Recruiting NCT07434635

APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes

Phase IV Interventional Eye Disorders

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Atropine 1%.
Who it may be relevant to
Registry conditions: Eye Disorders. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The study will evaluate whether atropine eyedrops are beneficial when used after certain eye surgeries.

Detailed description

Atropine eyedrops are often used after certain eye surgeries. This study will compare several outcomes following surgery in patients either using or not using this treatment.

Interventions

  • Drug Atropine 1%
    Subtraction of atropine eyedrops from post-operative treatment regimen

Primary outcome measures

  • Pain score on the Visual Analog Scale (VAS) [Time frame: 1 month]
Secondary outcome measures (5)
  • Anterior chamber inflammation (aqueous cell and flare) [Time frame: 1 month]
  • Cystoid macular edema detected by optical coherence tomography [Time frame: 1 month]
  • Time to visual recovery [Time frame: 1 month]
  • Intraocular pressure [Time frame: 1 month]
  • Posterior synechiae formation [Time frame: 1 month]

Eligibility criteria

Inclusion criteria

  • patient undergoing vitrectomy surgery
  • able to give informed consent

Exclusion criteria

  • post-operative eyedrop regimens that include topical non steroidal anti-inflammatory medications
  • subjects with altered post-operative eyedrop schedule for enhanced inflammation control
  • documented allergy to atropine

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • University of California, San Francisco — San Francisco

Identifiers

NCT: NCT07434635 · 25-45406

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗